Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel

EARLY_PHASE1SuspendedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2025

Study Completion Date

December 31, 2025

Conditions
Menstrual Symptoms
Interventions
DEVICE

Implanon NXT® subdermal implant

"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"

DRUG

Etonogestrel 68mg implant

"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"

Trial Locations (1)

04023-062

Department of Gynecology of Federal University of São Paulo, São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Organon

INDUSTRY

lead

Maíta Poli de Araújo

OTHER